BioCryst Pharmaceuticals (BCRX)

• Market cap: $1.68B
• 1 day: -1.93%
• 5 days: -12.96%
• 1 month: 1.50%
• 3 months: 11.83%
• 6 months: -1.22%
• Year to date: 3.83%
• 1 year: 40.41%
• 5 years: 258.15%
• 10 years: -23.08%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 531

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

42% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $8.5M

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

6% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 31

1% less funds holding

Funds holding: 255 [Q3] → 253 (-2) [Q4]

4% less capital invested

Capital invested by funds: $1.32B [Q3] → $1.26B (-$55.4M) [Q4]

2.78% less ownership

Funds ownership: 83.74% [Q3] → 80.96% (-2.78%) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 90

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 48% upside
• Avg. target: $18.60 129% upside
• High target: $30 269% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Jonathan Wolleben 0 / 0 met price target	121% upside $18	Market Outperform Reiterated	25 Feb 2025
HC Wainwright & Co. Andrew Fein 36% 1-year accuracy 127 / 352 met price target	269% upside $30	Buy Reiterated	25 Feb 2025
JMP Securities Jonathan Wolleben 0 / 0 met price target	121% upside $18	Market Outperform Reiterated	31 Jan 2025
Evercore ISI Group Liisa Bayko 79% 1-year accuracy 11 / 14 met price target	48% upside $12	Outperform Maintained	13 Jan 2025
Needham Serge Belanger 46% 1-year accuracy 58 / 125 met price target	85% upside $15	Buy Maintained	13 Jan 2025